Subtype
Digestive System Adenocarcinoma
CI-CAN-00002525Explore in graph →
1,374 active trials24 approved drugs77 evidence items
- NCIt
- C210140
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00002525Explore in graph →
Clinical trials
5,072 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (619)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05883176 | TACE Combined With Bevacizumab in HCC (BCLC-B) Beyond Up-To-Seven Criteria(B-TACE) | unknown | Phase 2 | 35 | Sun Yat-sen UniversityOTHER | 1 | May 31, 2023 | clinicaltrials |
| NCT05879328 | The ImmunoXXL Study(ImmunoXXL) | unknown | — | 12 | Fondazione IRCCS Istituto Nazionale dei Tumori, MilanoOTHER | 1 | May 30, 2023 |
| clinicaltrials |
| NCT05754788 | Gene Expression Profile of Resected Pancreatic and Ampullary Adenocarcinoma at Favorable Prognosis | unknown | — | 40 | Fondazione IRCCS Istituto Nazionale dei Tumori, MilanoOTHER | 1 | May 26, 2023 | clinicaltrials |
| NCT05875558 | M-TACE Treatment for Unresectable Hepatocellular Carcinoma | unknown | N/A | 40 | Shanghai Zhongshan HospitalOTHER | 1 | May 25, 2023 | clinicaltrials |
| NCT05876052 | HOPE to Reduce Tumour Recurrence After LT In Patients With HCC(POTERE) | unknown | N/A | 192 | University of BolognaOTHER | 1 | May 25, 2023 | clinicaltrials |
| NCT05872841 | H101 Combined With TACE for Primary Hepatocellular Carcinoma With Portal Vein Thrombosis | unknown | Phase 2 | 38 | Tianjin Medical University Cancer Institute and HospitalOTHER | 0 | May 24, 2023 | clinicaltrials |
| NCT05862181 | The Comparison Between HepaSphere Drug-eluting Bead Transarterial Chemoembolization Combined With Hepatic Arterial Infusion Chemotherapy in Advanced Hepatocellular Carcinoma | unknown | — | 200 | Peking University Cancer Hospital & InstituteOTHER | 1 | May 22, 2023 | clinicaltrials |
| NCT05866172 | HAIC Combined Withzoledronic Acid for the Prevention of Bone Metastases in Advanced HCC | unknown | Phase 3 | 264 | Sun Yat-sen UniversityOTHER | 1 | May 19, 2023 | clinicaltrials |
| NCT04967495 | TACE Plus Multikinase Inhibitor and I-125 Seeds Brachytherapy for HCC With Branch PVTT | unknown | N/A | 171 | Second Affiliated Hospital of Guangzhou Medical UniversityOTHER | 1 | May 18, 2023 | clinicaltrials |
| NCT05859945 | Navigating the Clinical Trial Process for Hepatocellular Carcinoma | unknown | — | 500 | Power Life Sciences Inc.INDUSTRY | 0 | May 16, 2023 | clinicaltrials |
| NCT04111029 | Liquid Biopsy in Hepatocellular Carcinoma(HCCGenePanel) | unknown | — | 30 | Post Graduate Institute of Medical Education and Research, ChandigarhOTHER | 1 | May 3, 2023 | clinicaltrials |
| NCT05837065 | Prognostic Models for HCC Based on Tumor Micronecrosis | unknown | — | 765 | Zhejiang UniversityOTHER | 1 | May 1, 2023 | clinicaltrials |
| NCT05134532 | Regorafenib After Progression on Atezolizumab Plus Bevacizumab in Advanced HCC(HCC) | unknown | Phase 2 | 40 | CHA UniversityOTHER | 1 | Apr 26, 2023 | clinicaltrials |
| NCT04164602 | The Occurence of Pancreatic Cancer Studied in Association With Newly Diagnosed Diabetes in the Elderly(NODES) | unknown | — | 2,522 | University of PecsOTHER | 1 | Apr 19, 2023 | clinicaltrials |
| NCT04652440 | Ablation Combined With PD-1 in HCC: Phase II Study | unknown | Phase 1 / Phase 2 | 30 | Sun Yat-sen UniversityOTHER | 1 | Apr 19, 2023 | clinicaltrials |
| NCT05816863 | Clinical Study of Pabolizumab for Neoadjuvant Immunotherapy of Locally Advanced Microsatellite-unstable Gastric Adenocarcinoma | unknown | — | 32 | Peking University Cancer Hospital & InstituteOTHER | 1 | Apr 18, 2023 | clinicaltrials |
| NCT05093920 | Role of DEB-TACE Versus c-TACE in Treatment of HCC | unknown | Early Phase 1 | 30 | Sohag UniversityOTHER | 1 | Apr 12, 2023 | clinicaltrials |
| NCT05809869 | Immunotherapy and Radioembolisation for Metastatic Hepatocellular Carcinoma | unknown | Phase 2 | 25 | The University of Hong KongOTHER | 1 | Apr 12, 2023 | clinicaltrials |
| NCT05690958 | Public's Intended Uptake and Views on Organization of Esophageal Cancer Screening(ACCEPT-survey) | unknown | — | 2,088 | Radboud University Medical CenterOTHER | 1 | Apr 5, 2023 | clinicaltrials |
| NCT05800236 | Characterisation of the Intratumoral Microbiome in Gastric Adenocarcinoma: to a Personalised Medicine(MICROGAS) | unknown | N/A | 20 | University Hospital, BordeauxOTHER | 1 | Apr 5, 2023 | clinicaltrials |
| NCT05800561 | Prognostic Role of HVPG and ICG-R15 in the Short- and Medium-term Results of the Surgery of HCC on Cirrhosis(ProHype-ICG) | unknown | — | 208 | Federico II UniversityOTHER | 1 | Apr 5, 2023 | clinicaltrials |
| NCT04601961 | Effects of TIVA Versus Inhalational Anaesthesia on Circulating Tumour Cells in Hepatocellular Carcinoma Patients | unknown | N/A | 220 | The University of Hong KongOTHER | 1 | Mar 31, 2023 | clinicaltrials |
| NCT04368078 | Lenvatinib Combined Toripalimab in Advanced Hepatocellular Carcinoma | unknown | Phase 2 | 76 | Peking Union Medical College HospitalOTHER | 1 | Mar 29, 2023 | clinicaltrials |
| NCT04443309 | Lenvatinib in Combination With Camrelizumab as First-Line Therapy in Patients With Advanced HCC | unknown | Phase 1 / Phase 2 | 53 | Peking Union Medical College HospitalOTHER | 1 | Mar 29, 2023 | clinicaltrials |
| NCT05048017 | Regorafenib Combined With PD-1 Inhibitor Therapy for Second-line Treatment of Hepatocellular Carcinoma | unknown | Phase 2 | 20 | Peking Union Medical College HospitalOTHER | 1 | Mar 29, 2023 | clinicaltrials |
| NCT05670561 | Effects of Esketamine on Acute Abdominal Pain After TACE in Patients With Hepatocellular Carcinoma | unknown | Phase 4 | 60 | The Second Affiliated Hospital of Chongqing Medical UniversityOTHER | 1 | Mar 29, 2023 | clinicaltrials |
| NCT04663035 | Ablation Plus Tislelizumab Versus Ablation Alone for Intrahepatic Recurrent Early Stage HCC | unknown | Phase 2 | 120 | Ming ZhaoOTHER | 1 | Mar 22, 2023 | clinicaltrials |
| NCT05407519 | A Study to Evaluate Tislelizumab Combined With Sitravatinib as Adjuvant Therapy in Participants With HCC at High Risk of Recurrence After Curative Resection | unknown | Phase 2 | 40 | Anhui Provincial HospitalOTHER_GOV | 1 | Mar 22, 2023 | clinicaltrials |
| NCT05616390 | Sintilimab Combined With Bevacizumab and Liver Protective Support Therapy in Unresectable Hepatocellular Carcinoma | unknown | Phase 2 | 30 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Mar 21, 2023 | clinicaltrials |
| NCT05764551 | The Application of Serum DNA Methylation for Patients With HCC | unknown | N/A | 100 | Chiayi Christian HospitalOTHER | 1 | Mar 21, 2023 | clinicaltrials |
| NCT05770635 | Polyvinyl Alcohol Embolization Microspheres | unknown | N/A | 224 | Shanghai Huihe Medical Technology Co., LtdINDUSTRY | 1 | Mar 15, 2023 | clinicaltrials |
| NCT05408221 | the Efficacy and Safety of Rulonilimab in Combination With Lenvatinib in Hepatocellular Carcinoma(HCC) | unknown | Phase 2 / Phase 3 | 576 | Shandong New Time Pharmaceutical Co., LTDINDUSTRY | 1 | Mar 10, 2023 | clinicaltrials |
| NCT05429866 | Immunological Variables Associated to ICI Toxicity in Cancer Patients | unknown | Phase 2 | 441 | Jules Bordet InstituteOTHER | 1 | Mar 8, 2023 | clinicaltrials |
| NCT05759858 | Identification and Prognostic Value of Key Genes in Hepatocellular Carcinoma | unknown | — | 100 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Mar 8, 2023 | clinicaltrials |
| NCT05760430 | The Synergistic Effect of Portal Venous Supply Control and Immunotherapy in Hepatocellular Carcinoma | unknown | Phase 2 | 40 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Mar 8, 2023 | clinicaltrials |
| NCT05760599 | Candonilimab Plus Bevacizumab for Patients With Advanced HCC Who Progressed on A+T | unknown | Phase 2 | 30 | Shi MingOTHER | 1 | Mar 8, 2023 | clinicaltrials |
| NCT05675462 | Oncolytic Virotherapy Plus PD-1 Inhibitor and Lenvatinib as Second-line or Later Therapy in Patients With Advanced Hepatocellular Carcinoma | unknown | Phase 1 | 25 | Fudan UniversityOTHER | 1 | Mar 6, 2023 | clinicaltrials |
| NCT03475953 | A Phase I/II Study of Regorafenib Plus Avelumab in Solid Tumors(REGOMUNE) | unknown | Phase 1 / Phase 2 | 747 | Institut BergoniéOTHER | 1 | Mar 3, 2023 | clinicaltrials |
| NCT05536427 | Safety and Efficacy of IPM001 in Patients With Advanced Hepatocellular Carcinoma | unknown | Phase 1 | 24 | Peking Union Medical College HospitalOTHER | 1 | Mar 2, 2023 | clinicaltrials |
| NCT05416073 | Effect of Esketamine on Abdominal Pain During TACE-HAIC in Patients With Hepatocellular Carcinoma(TACE-HAIC) | unknown | Phase 4 | 70 | The Second Affiliated Hospital of Chongqing Medical UniversityOTHER | 1 | Feb 24, 2023 | clinicaltrials |
| NCT05738447 | Application of mRNA Immunotherapy Technology in Hepatitis B Virus-related Refractory Hepatocellular Carcinoma | unknown | Phase 1 | 9 | West China HospitalOTHER | 1 | Feb 22, 2023 | clinicaltrials |
| NCT05738772 | Diagnostic Accuracy of APAC, ASAP and GALAD Scores in Hepatocellular Carcinoma Among Cirrhotic Patients | unknown | — | 90 | Sohag UniversityOTHER | 1 | Feb 22, 2023 | clinicaltrials |
| NCT03399071 | Study Title: Peri-operative Immuno-Chemotherapy in Operable Oesophageal and Gastric Cancer(ICONIC) | unknown | Phase 2 | 44 | Royal Marsden NHS Foundation TrustOTHER | 1 | Feb 21, 2023 | clinicaltrials |
| NCT04387695 | SBRT+TACE+Sorafenib Vs Sorafenib in the Treatment of uHCC With PVTT | unknown | Phase 3 | 54 | First Affiliated Hospital of Zhejiang UniversityOTHER | 1 | Feb 16, 2023 | clinicaltrials |
| NCT04992143 | TACE+Tilelizumab+Sorafenib in the Treatment of BCLC Stage C HCC | unknown | Phase 2 | 20 | First Affiliated Hospital of Zhejiang UniversityOTHER | 1 | Feb 16, 2023 | clinicaltrials |
| NCT05729867 | Efficacy and Safety of a Fully Covered Self-Expandable Metal Stent for Unresectable HCC | unknown | N/A | 50 | Seoul National University HospitalOTHER | 1 | Feb 16, 2023 | clinicaltrials |
| NCT03766555 | Microwave Ablation Versus Liver Resection For Early Hepatocellular Carcinoma in Patients With Borderline Liver Function | unknown | N/A | 76 | Chinese University of Hong KongOTHER | 1 | Feb 13, 2023 | clinicaltrials |
| NCT05543304 | Predicting Response to Systemic Therapies for Hepatocellular Carcinoma(HCC) | unknown | — | 200 | First Affiliated Hospital of Wenzhou Medical UniversityOTHER | 1 | Feb 13, 2023 | clinicaltrials |
| NCT05721300 | Study on Screening, Verification and Intervention of High-risk Patients With Liver Cancer | unknown | N/A | 2,215 | Zhongshan Hospital (Xiamen), Fudan UniversityOTHER | 1 | Feb 10, 2023 | clinicaltrials |
Data updated 23 days agoSource updated May 31, 2023source: clinicaltrials